A new position paper proposes measuring specific bone turnover markers (BTMs) in patients who have initiated use of oral bisphosphonates for postmenopausal osteoporosis as a practical way to identify low adherence. BTMs can reflect the early effect of the drug on bone tissue. If low response is detected shortly after treatment begins, this may indicate low adherence or point to underlying causes of impaired response to medication.